These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 25625880)

  • 1. Apixaban is dear to me, but dearer still is warfarin.
    Di Biase L; Natale A
    Pacing Clin Electrophysiol; 2015 Feb; 38(2):153-4. PubMed ID: 25625880
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation.
    Nagao T; Inden Y; Shimano M; Fujita M; Yanagisawa S; Kato H; Ishikawa S; Miyoshi A; Okumura S; Ohguchi S; Yamamoto T; Yoshida N; Hirai M; Murohara T
    Pacing Clin Electrophysiol; 2015 Feb; 38(2):155-63. PubMed ID: 25487164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of pre-procedural interrupted apixaban on heparin anticoagulation during catheter ablation for atrial fibrillation: a prospective observational study.
    Bin Abdulhak AA; Kennedy KF; Gupta S; Giocondo M; Ramza B; Wimmer AP
    J Interv Card Electrophysiol; 2015 Nov; 44(2):91-6. PubMed ID: 26292959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study.
    Di Biase L; Lakkireddy D; Trivedi C; Deneke T; Martinek M; Mohanty S; Mohanty P; Prakash S; Bai R; Reddy M; Gianni C; Horton R; Bailey S; Sigmund E; Derndorfer M; Schade A; Mueller P; Szoelloes A; Sanchez J; Al-Ahmad A; Hranitzky P; Gallinghouse GJ; Hongo RH; Beheiry S; Pürerfellner H; Burkhardt JD; Natale A
    Heart Rhythm; 2015 Jun; 12(6):1162-8. PubMed ID: 25728754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon.
    Kaess BM; Ammar S; Reents T; Dillier R; Lennerz C; Semmler V; Grebmer C; Bourier F; Buiatti A; Kolb C; Deisenhofer I; Hessling G
    Am J Cardiol; 2015 Jan; 115(1):47-51. PubMed ID: 25456870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation.
    Shah RR; Pillai A; Schafer P; Meggo D; McElderry T; Plumb V; Yamada T; Kumar V; Doppalapudi H; Gunter A; Pentecost E; Maddox WR
    Am J Cardiol; 2017 Aug; 120(3):404-407. PubMed ID: 28595862
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial.
    Held C; Hylek EM; Alexander JH; Hanna M; Lopes RD; Wojdyla DM; Thomas L; Al-Khalidi H; Alings M; Xavier D; Ansell J; Goto S; Ruzyllo W; Rosenqvist M; Verheugt FW; Zhu J; Granger CB; Wallentin L
    Eur Heart J; 2015 May; 36(20):1264-72. PubMed ID: 25499871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial.
    Reynolds MR; Allison JS; Natale A; Weisberg IL; Ellenbogen KA; Richards M; Hsieh WH; Sutherland J; Cannon CP
    JACC Clin Electrophysiol; 2018 May; 4(5):580-588. PubMed ID: 29798783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation.
    Yoshimura A; Iriki Y; Ichiki H; Oketani N; Okui H; Maenosono R; Namino F; Miyata M; Ohishi M
    J Cardiol; 2017 Jan; 69(1):228-235. PubMed ID: 27131792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Premature permanent discontinuation of apixaban or warfarin in patients with atrial fibrillation.
    Carnicelli AP; Al-Khatib SM; Xavier D; Dalgaard F; Merrill PD; Wojdyla DM; Lewis BS; Hanna M; Alexander JH; Lopes RD; Wallentin L; Granger CB
    Heart; 2021 May; 107(9):713-720. PubMed ID: 32938772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of apixaban compared with warfarin as gain in event-free time - a novel assessment of the results of the ARISTOTLE trial.
    Berglund E; Wallentin L; Oldgren J; Renlund H; Alexander JH; Granger CB; Hohnloser SH; Hylek EM; Lopes RD; McMurray JJ; Lytsy P
    Eur J Prev Cardiol; 2020 Aug; 27(12):1311-1319. PubMed ID: 31698965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apixaban for periprocedural anticoagulation during catheter ablation of atrial fibrillation: a systematic review and meta-analysis of 1691 patients.
    Blandino A; Bianchi F; Biondi-Zoccai G; Grossi S; Conte MR; Rametta F; Gaita F
    J Interv Card Electrophysiol; 2016 Sep; 46(3):225-36. PubMed ID: 27217030
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Which oral anticoagulant for atrial fibrillation.
    Med Lett Drugs Ther; 2016 Apr; 58(1492):45-6. PubMed ID: 27049507
    [No Abstract]   [Full Text] [Related]  

  • 14. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.
    Flaker G; Lopes RD; Hylek E; Wojdyla DM; Thomas L; Al-Khatib SM; Sullivan RM; Hohnloser SH; Garcia D; Hanna M; Amerena J; Harjola VP; Dorian P; Avezum A; Keltai M; Wallentin L; Granger CB;
    J Am Coll Cardiol; 2014 Oct; 64(15):1541-50. PubMed ID: 25301455
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral anticoagulant use around the time of atrial fibrillation ablation: a review of the current evidence of individual oral anticoagulant use for periprocedural atrial fibrillation ablation thromboembolic prophylaxis.
    Garton AB; Dudzinski J; Kowey PR
    J Cardiovasc Electrophysiol; 2014 Dec; 25(12):1411-8. PubMed ID: 25216104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do not stop the warfarin until ..
    Cakulev I; Waldo AL
    J Am Coll Cardiol; 2010 Feb; 55(8):744-6. PubMed ID: 20170811
    [No Abstract]   [Full Text] [Related]  

  • 17. Differences in prothrombotic response between the uninterrupted and interrupted apixaban therapies in patients undergoing cryoballoon ablation for paroxysmal atrial fibrillation: a randomized controlled study.
    Ando M; Inden Y; Yoshida Y; Sairaku A; Yanagisawa S; Suzuki H; Watanabe R; Takenaka M; Maeda M; Murohara T
    Heart Vessels; 2019 Sep; 34(9):1533-1541. PubMed ID: 30840130
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.
    Wallentin L; Lopes RD; Hanna M; Thomas L; Hellkamp A; Nepal S; Hylek EM; Al-Khatib SM; Alexander JH; Alings M; Amerena J; Ansell J; Aylward P; Bartunek J; Commerford P; De Caterina R; Erol C; Harjola VP; Held C; Horowitz JD; Huber K; Husted S; Keltai M; Lanas F; Lisheng L; McMurray JJ; Oh BH; Rosenqvist M; Ruzyllo W; Steg PG; Vinereanu D; Xavier D; Granger CB;
    Circulation; 2013 Jun; 127(22):2166-76. PubMed ID: 23640971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apixaban compared with warfarin for stroke prevention in atrial fibrillation: implications of time in therapeutic range.
    Gallego P; Vilchez JA; Lane DA
    Circulation; 2013 Jun; 127(22):2163-5. PubMed ID: 23640972
    [No Abstract]   [Full Text] [Related]  

  • 20. Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: A meta-analysis.
    Phan K; Wang N; Pison L; Kumar N; Hitos K; Thomas SP
    Int J Cardiol; 2015 Apr; 185():209-13. PubMed ID: 25797679
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.